<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019381</url>
  </required_header>
  <id_info>
    <org_study_id>13005</org_study_id>
    <nct_id>NCT02019381</nct_id>
  </id_info>
  <brief_title>Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.</brief_title>
  <official_title>The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently two distinguished committees, Institute of Medicine (IOM) and The Endocrine Society&#xD;
      have proposed different intake guidelines for Calcium and Vitamin D. We wish to compare the&#xD;
      effects of both of them on calcium metabolism and bone turnover. We propose a one year&#xD;
      randomized double blinded study for the same.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this study proposal are to determine the following:&#xD;
&#xD;
        1. To compare the two different intake guidelines for Calcium and Vitamin D Supplementation&#xD;
           at its recommended tolerable upper limit on serum and urinary calcium in white&#xD;
           postmenopausal Women.&#xD;
&#xD;
        2. Compare the effects above mentioned two intake guidelines on Vitamin D metabolism&#xD;
           [25(OH)D, 1,25(OH)2D] and bone turnover.&#xD;
&#xD;
      Participants will be randomly assigned to Group A or Group B based on different dosages of&#xD;
      study medications.&#xD;
&#xD;
      Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D +&#xD;
      Two pills Calcium containing 600mg calcium each.&#xD;
&#xD;
      Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D&#xD;
&#xD;
      + Two pills Calcium containing 600mg calcium each.&#xD;
&#xD;
      In addition to the calcium supplements, they will guide to include approximately 800mg of&#xD;
      calcium in their daily diet.&#xD;
&#xD;
      At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for&#xD;
      collection of 24-hour urine for urinary calcium to be brought in next day. Study medication&#xD;
      will be dispensed and participants will be asked not to discard unused medications and to&#xD;
      bring all study medications next study visit.&#xD;
&#xD;
      Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused&#xD;
      study medication and given new tablets each visit. Except on visit 6 no further study&#xD;
      medications will be dispensed, after collecting the previous supply.&#xD;
&#xD;
      Food frequency questionnaires will be filled out at the initial visit and final visit. Diet&#xD;
      will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients&#xD;
      will be asked to refrain from taking other Vitamin D supplements and to continue their usual&#xD;
      calcium intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).</measure>
    <time_frame>One year</time_frame>
    <description>Endocrine society has recommended tolerable upper limit or a dose with no adverse events as 10,000IU of Vitamin D and 2000 mg/day of calcium. Our study will test the safety/ efficacy of this recommendation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.</measure>
    <time_frame>One year</time_frame>
    <description>To test safety/efficacy of The Endocrine Society recommendations on Bone turnover.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Delusion of Reference</condition>
  <arm_group>
    <arm_group_label>Endocrine Society UL Dosage Vitamin D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Institute of Medicine Dosage Vitamin D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Endocrine Society UL Dosage Vitamin D</intervention_name>
    <description>Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium</description>
    <arm_group_label>Endocrine Society UL Dosage Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Institute of Medicine Dosage Vitamin D</intervention_name>
    <description>IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium</description>
    <arm_group_label>Institute of Medicine Dosage Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>1200mg of CaCO3 supplementation will be given to each participant in both groups</description>
    <arm_group_label>Endocrine Society UL Dosage Vitamin D</arm_group_label>
    <arm_group_label>Institute of Medicine Dosage Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy White women aged 50 and older who have been postmenopausal for at least 2 year&#xD;
             (i.e. absence of menstrual period for a period of 24 months or more).&#xD;
&#xD;
          2. Willingness to discontinue self-administration of vitamin D and calcium supplements.&#xD;
             Participants must be at least three months off supplements before starting the study.&#xD;
&#xD;
          3. Willingness to take study medications and participate in study for one year.&#xD;
&#xD;
          4. Written informed Consent Signed.&#xD;
&#xD;
          5. Patients with hypertension and diabetes stable for last three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypercalciuria (24-hour urinary calcium excretion &gt;250 mg), hypercalcemia&#xD;
             (serum calcium &gt;10.6), nephrolithiasis and active sarcoidosis will be excluded.&#xD;
&#xD;
          2. Serum 25-hydroxyvitamin D level &gt;80 nmol/L or history of primary hyperparathyroidism.&#xD;
&#xD;
          3. Dietary calcium intake of &gt;2000mg/day will be excluded&#xD;
&#xD;
          4. Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant&#xD;
             medications, glucocorticoids, Highly Active AntiRetroviral Therapy [AIDS treatment],&#xD;
             antirejection medications, chronic use of steroids, high dose diuretics)&#xD;
&#xD;
          5. Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators,&#xD;
             Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic&#xD;
             steroids 6 months prior to the study.&#xD;
&#xD;
          6. Use of systemic steroids (oral or intravenous) within the last year at an average dose&#xD;
             of more than 5mg/day of oral prednisone or an equivalent for a period of three months&#xD;
             or more prior to screening.&#xD;
&#xD;
          7. Chronic medical illness including Chronic liver disease, uncontrolled diabetes&#xD;
             mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or&#xD;
             active malignancy; uncontrolled hypertension; obesity (BMI&gt;35 kg/m2); malabsorption,&#xD;
             anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis,&#xD;
             sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone&#xD;
             disease.&#xD;
&#xD;
          8. Unexplained weight loss of &gt;15% during the previous year or history of anorexia&#xD;
             nervosa&#xD;
&#xD;
          9. &gt; 1 pack per day tobacco use or &gt; 2 alcoholic beverages per day&#xD;
&#xD;
         10. Unwillingness to forego self-administration of vitamin D and calcium-containing&#xD;
             supplements.&#xD;
&#xD;
         11. Participation in another investigational trial in the past 30 days prior to the&#xD;
             screening evaluation&#xD;
&#xD;
         12. Significant deviation from normal in medical history, physical examination, or&#xD;
             laboratory tests as evaluated by the primary investigator.&#xD;
&#xD;
         13. Patients with unstable hypertension or diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Aloia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mageda Mikhail, MD</last_name>
    <role>Study Director</role>
    <affiliation>Winthrop UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Winthrop University Hospital</investigator_affiliation>
    <investigator_full_name>John F. Aloia, MD</investigator_full_name>
    <investigator_title>Chief Academic Officer, MD, Endocrinology.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delusions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

